CN106912940A - A kind of composition containing L-arabinose and application thereof - Google Patents
A kind of composition containing L-arabinose and application thereof Download PDFInfo
- Publication number
- CN106912940A CN106912940A CN201511020264.4A CN201511020264A CN106912940A CN 106912940 A CN106912940 A CN 106912940A CN 201511020264 A CN201511020264 A CN 201511020264A CN 106912940 A CN106912940 A CN 106912940A
- Authority
- CN
- China
- Prior art keywords
- extract
- mulberry
- green coffee
- arabinose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 title claims abstract description 29
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 74
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 14
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 14
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 14
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 14
- 229940074393 chlorogenic acid Drugs 0.000 claims description 14
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 14
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 14
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 14
- 235000000346 sugar Nutrition 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 230000036541 health Effects 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000003345 hyperglycaemic effect Effects 0.000 abstract description 2
- 230000035622 drinking Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 13
- 206010033307 Overweight Diseases 0.000 description 12
- 239000012467 final product Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 240000000249 Morus alba Species 0.000 description 10
- 235000008708 Morus alba Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001835 salubrious effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of composition containing L-arabinose, belong to field of food.A kind of composition, is made up of L-arabinose 1-4 weight portions, green coffee-extract 1-4 weight portions and L- mulberry-leaf extract 1-4 weight portions.The invention has the advantages that, significantly, drinking can reduce fat absorption for a long time for said composition auxiliary hyperglycemic, auxiliary lipid-lowering effect.Raw material is edible, with good security.The product meets the consumption idea that present consumer focuses on health, with good market prospects.
Description
Technical field
The present invention relates to a kind of composition containing L-arabinose and application thereof, belong to field of health care food.
Background technology
It is fat by the World Health Organization it is expressly intended that be the maximum chronic disease in the whole world, and by itself and AIDS, inhale
Poison, excessive drinking together, are listed as the big medical science social concern in the world four.It is reported that the fat and overweight total people in the current whole world
Mouth has reached 1,200,000,000, and will be increased with every speed doubled for 5 years.It is continuous with China's national life level
Improve, the fat and overweight number of China steeply rises.Chinese residents nutrition and health survey result shows, mistake
Between going 10 years, rate that Chinese urban and rural residents are overweight and obesity rates respectively than 10 years before rise 36.7% and 83.9%.According to
《Chinese residents nutrition and investigation of health conditions are reported》In data, weighed according to international body mass index,
Just there is 1 people's overweight in every 5 adults of China, just there is 1 people to be judged as obese people in every 10 people.This meaning
Taste, and Chinese overweight number is likely to be breached 200,000,000 people, and population of being obese number is likely to be breached 90,000,000.And from 2000
Rise, the big city of developed regions just enters the fat epizootic modeling of minor comprehensively.With the big provinces and cities in Beijing etc. six
As a example by city primary school boy student, its fat incidence is 12.9%, and this numeral is already close to the level of medium-developed country.
Tianjin also specially starts children obesity examination and intervention project for this, and the comprehensive prevention for having carried out children obesity is done
Pre-operation.
It is fat and it is overweight be not the excessive problem of single fat generation, but can be drawn by the effect of organism metabolism
The exception of whole body multiple system is played, huge threat especially is brought to the circulatory system, digestive system and respiratory system.Fertilizer
Fat is the influence factor of various chronic diseases, it is not only possible to cause diabetes, angiocardiopathy, gallbladder disease, courage high
The incidence of disease of the illnesss such as sterol, apoplexy, arthritis rises, and has a strong impact on the healthy and quality of life of resident.
Obesity is the Major Risk Factors of many serious diseases：57% non-insulin-dependent (2 type) diabetes；30%
Gallbladder disease；17% coronary heart disease；17% hypertension；14% osteoarthritis；11% breast cancer/uterus/colon
The carcinoma of the rectum.Obesity can also cause sleep-disordered breathing.Overweight people compared with non-obese person, diabetes, cardiovascular disease
The sick incidence of disease significantly increases, suffer from sudden death, cerebral apoplexy, the relative risk of coronary heart disease and congestive heart failure be respectively 2.8,
2.0th, 1.5 and 1.9 times, the danger of diabetes is suffered from for 2-10 times, the danger for suffering from hypertension is 10 times.It is fat and overweight
The Dyslipidemia for bringing can have a strong impact on liver and cardiovascular system, and Beijing is to some overweight peoples in students in middle and primary schools
Detection fatty liver and liver function find that its 10% people reaches the diagnostic criteria of clinical fat liver, and this ratio is normal
51 times of body weight children.In addition it is fat and overweight the disease such as be also easy to trigger joint disease, gall stone and respiratory function low
Disease, the health care belt for giving people carrys out very big threat.The problem of the lifestyle diseases such as obesity, not only influence people health and
Life, and significant impact is all produced to China's medical security, social pension, medical resource distribution pattern etc..
The reason for causing obesity is not yet completely clear and definite at present, but it is sure that, carbohydrate and fat intake are excessively
Promote the fat key factor for being formed, sugar high, high fat diet can lead obesogenous formation.
L-arabinose is a kind of new functional form sweetener low in calories, and taste and sucrose are closely similar, and it is most notable
Effect be the activity for suppressing invertase in human small intestine, regulation absorption of the human body to sucrose fundamentally controls blood sugar
And blood lipid level.Sucrose is absorbed competitive inhibitory effect, has notable blocking effect to the metabolic conversion of carbohydrate.Grind
Study carefully and show, as long as adding 2% L-arabinose in common sucrose, it is possible to suppress the absorption of 50% sucrose, while
Suppress the rising of blood sugar, therefore can be used for mitigating the diseases such as fat, treatment diabetes and hypertension.
Mulberry leaf are the dried leaf of Moraceae fallen leaves property xylophyta mulberry (Morus alba L) for many years, and China is rich to produce, medicine-food two-purpose.
Traditionally as dispelling wind and heat from the body, clearing away the lungheat and moisturizing, suppressing liver-YANG, the Chinese medicine for clearing liver and improving vision is used the traditional Chinese medical science.Mulberry leaf sheet
It is the staple food material bred silkworms, in recent years, Kanagawa, Japan functional food research institute it was discovered by researchers that mulberry leaf are
Kind first-class food material, it has suppression blood sugar to rise, reduces cholesterol, suppressing intestinal toxic bacterial reproduction,
Defaecation, hypotensive, anti-cancer, the accumulation of suppression body fat, suppression thrombus generate, suppress to be harmful to the peroxide of human body
Generation and preventing life style-related diseases, maintenance and salubrious effect.Various nutritions are rich in mulberry leaf, also containing class
Flavones and DNJ Alkaloids.DNJ Alkaloids are less particular matters in other animals and plants, itself not by
Absorption of human body, but played a role by suppressing in human body intestinal canal alpha-glucosidase.Alpha-glucosidase is called α-D
Glucoside hydrolase.It can cut glucose from the non-reducing end of polysaccharide, disaccharides.Can be by the starch in enteron aisle
Class carbohydrate breakdown is dependent on α-grape in enteron aisle into glucose, final digestion of the human body to carbohydrate foods such as starch
The effect of glycosidase.DNJ can effectively delay the degradation rate of starch in enteron aisle, make to come the Portugal of self-carbon water compound
The degraded of grape sugar and absorbed into serum slow, and delay the rising of postprandial blood sugar.
Green coffee-extract is a kind of newfound fat-reducing replenishers.Male rat feeding is carried containing green coffee respectively
Take the feed of thing 14 days, the liver triglycerides in rat body is detected, as a result show that green coffee-extract is inhibited
Rat body weight increases the accumulation with interior fat.Respectively to health volunteer and overweight subject, by three-dimensional double blinding with
Suppression increased weight effect of the machine cross matching to green coffee-extract is studied, and as a result shows green coffee-extract
The blood sugar concentration of normal subjects can be significantly reduced, while comparing normal coffee group, green coffee-extract is significantly reduced
The body weight of overweight subject.Proved using the method for random, double blinding, blank, linear dosage, cross matching
The fat-reducing effect of green coffee-extract, into 16 subject's average weights reduction by 8% of experiment, and does not find
Adverse reaction.
Not yet have with L-arabinose as Main Ingredients and Appearance at present, simultaneously the drop containing mulberry-leaf extract and green coffee-extract
Sugar, antihyperlipidemic product.
The content of the invention
The technical problem to be solved in the present invention is to provide a kind of composition of the hypoglycemic containing L-arabinose.
To achieve the above object, the present invention uses following technical scheme：
A kind of composition, by L-arabinose 1-4 weight portions, green coffee-extract 1-4 weight portions and mulberry-leaf extract
1-4 weight portions are constituted.
Described composition, preferably by L-arabinose 2-4 weight portions, green coffee-extract 1-2 weight portions and mulberry leaf
Extract 1-2 weight portions are constituted.
Described composition, is most preferably carried by the weight portion of L-arabinose 3, the weight portion of green coffee-extract 2 and mulberry leaf
Take the weight portion of thing 1 composition.
Edible various auxiliary materials and/or flavouring can also be contained in the composition, be made respectively with the present composition
Plant regular dosage form.The consumption of auxiliary material and/or flavouring is conventional amount used.
The auxiliary material is included but is not limited to：Starch, microcrystalline cellulose, sucrose, Aspartame, xylitol, trichlorine sugarcane
Sugar, stevioside, dextrin, lactose, glucose, sodium chloride, sodium carboxymethylcellulose, PVPP,
It is any one in magnesium stearate, superfine silica gel powder, vitamin C, cysteine, citric acid, sorbierite and sodium sulfite
Plant or several.
The formulation is included but is not limited to：Powder, pulvis, tablet, granule, capsule, oral liquid, beverage etc..
The preparation method of the composition, take L-arabinose 1-4 weight portions, green coffee-extract 1-4 weight portions and
Mulberry-leaf extract 1-4 weight portions are constituted, and all raw materials are well mixed, and are obtained final product.
Described composition, preferably by L-arabinose 2-4 weight portions, green coffee-extract 1-2 weight portions and mulberry leaf
Extract 1-2 weight portions are constituted.
Described composition, the most preferably weight portion of L-arabinose 3, the weight portion of green coffee-extract 2 and mulberry leaf are extracted
The weight portion of thing 1 is constituted.
The green coffee-extract, the mass percentage content of its contained total chlorogenic acid is 10-70%, preferably 20-50%,
Most preferably 20% or 50%.
The mulberry-leaf extract, the mass percentage content 0.1-10% of its contained DNJ (1-DNJ), preferably
0.5-5%, most preferably 1% or 5%.
Described composition, the purposes of blood sugar, the food of reduction blood fat or medicine is reduced for preparing.
The present composition is oral formulations, and the dose of recommendation is daily 1-4 grams (being free of auxiliary material), daily 2-4 times.
It is an advantage of the invention that：Under prescription of the present invention proportioning, good auxiliary hyperglycemic, auxiliary reducing blood lipid are respectively provided with
Effect.In the case where substantially normal diet is not changed, the absorption of carbohydrate can be effectively reduced, realize lowering blood-fat and reducing weight
Effect.Present composition lowering blood-fat and reducing weight effect is significant, long-term use can reduce fat and sugar absorption.Raw material
With edible, with good security.The product meets the consumption idea that present consumer focuses on health, with good
Market prospects.
The present invention is described in detail below by way of specific embodiment, practical range of the invention is not limited with this.
Specific embodiment
Embodiment 1
First, it is formulated
The green coffee-extract 20g mulberry-leaf extracts 10g of L-arabinose 30g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 50%, and DNJ contents are 1% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 2
First, it is formulated
The green coffee-extract 20g mulberry-leaf extracts 10g of L-arabinose 30g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 20%, and DNJ contents are 5% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 3
First, it is formulated
The green coffee-extract 20g mulberry-leaf extracts 20g of L-arabinose 20g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 50%, and DNJ contents are 1% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 4
First, it is formulated
The green coffee-extract 10g mulberry-leaf extracts 20g of L-arabinose 20g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 20%, and DNJ contents are 5% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 5
First, it is formulated
The green coffee-extract 10g mulberry-leaf extracts 10g of L-arabinose 20g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 50%, and DNJ contents are 1% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 6
First, it is formulated
The green coffee-extract 30g mulberry-leaf extracts 30g of L-arabinose 40g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 20%, and DNJ contents are 0.5% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 7
First, it is formulated
The green coffee-extract 20g mulberry-leaf extracts 10g of L-arabinose 40g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 50%, and DNJ contents are 2% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 8
First, it is formulated
The green coffee-extract 10g mulberry-leaf extracts 20g of L-arabinose 40g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 20%, and DNJ contents are 3% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 9
First, it is formulated
The green coffee-extract 40g mulberry-leaf extracts 30g of L-arabinose 40g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 30%, and DNJ contents are 4% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 10
First, it is formulated
The green coffee-extract 20g mulberry-leaf extracts 10g of L-arabinose 10g
Wherein：Green coffee-extract Content of Chlorogenic Acid is 40%, and DNJ contents are 1% in mulberry-leaf extract.
2nd, preparation method
Three kinds of components of formula ratio are well mixed, are obtained final product.
Embodiment 11：A kind of tablet of blood lipid-reducing blood sugar-decreasing
The composition 60g of embodiment 1, adds lactose 20g, microcrystalline cellulose 20g, superfine silica gel powder 0.1g, after mixing
Direct tablet compressing, obtains final product according to a conventional method.
Embodiment 12：A kind of capsule of blood lipid-reducing blood sugar-decreasing
The composition 60g of embodiment 2, adds lactose 20g, starch 10g, dextrin 10g, with 50% ethanol routinely
Method is pelletized, filling capsule.
Embodiment 13：A kind of pulvis of blood lipid-reducing blood sugar-decreasing
The composition 60g of embodiment 1, adds mannitol 20g, lactose 10g, citric acid 2g, Aspartame 0.1g,
It is well mixed, pack.
Embodiment 14：Hypoglycemic effect experiment
First, experiment material
1st, experimental animal
Male SD rat, 120~140g of original body mass, Beijing Vital River Experimental Animals Technology Co., Ltd. is qualified
Card number：SCXK (capital) 2012-0001.
2nd, nutrient fodder
Formula：80% basal feed, 10% lard, 10% yolk powder.
3rd, given the test agent
Composition containing L-arabinose prepared by embodiment 1
2nd, experimental technique
Male SD rat 70,10 feeding chow diets of blank control group, the 60 feeding nutrition of remaining modeling group
Feed, normal water.Continuous 6 weeks, weigh, modeling group compares with blank group, there is significant difference, point out fat
Model is successfully established.Modeling group 60 chooses the homogeneous rat of 40 body weight, and 4 groups are divided into immediately at random by body weight：
Model control group, the basic, normal, high dosage group of sample, every group 10.Blank control group continues feeding chow diet, its
Remaining each group continues feeding nutrient fodder, normal water.Sample sets gavage gives respective sample solution, and middle dose group is suitable
In 5 times of human body recommended dose, blank control group and model control group give pure water, and volume is 1ml/100g,
Successive administration 6 weeks, weekly last day calculate every food ration of rat.After off-test, each group rat is weighed,
Take around Rat renal and genitals (testis and epididymis) peripheral adipose, weigh weight in wet base, and calculate fat/body ratio, test
Result is counted with SPSS11.0.
Food ration (g)=inventory (g)-surplus (g)
Fat/body ratio=fat weight in wet base (g)/body weight (kg)
3rd, experimental result
Influence of the sample of table 1 to obese model rat body weight
Compare certainly with blank, #P ＜ 0.05, ##P ＜ 0.01；Compare with model control group,*P ＜ 0.05**P ＜ 0.01.256.8±15.7##
As shown in Table 1, before modeling, each group rat original body mass is homogeneous, difference that there are no significant；After modeling, feeding
The rat body weight of nutrient fodder has pole significant difference apparently higher than the rat of feeding chow diet, and hints model is set up
Success；Before administration, rat is grouped at random by body weight for modeling, and there was no significant difference between each group rat；During administration,
Model control group rat body weight has pole significant difference apparently higher than blank control group；After being administered 3 weeks, in sample,
High dose group rat body weight is less than model control group, there is significant difference；After being administered 6 weeks, sample is low, middle dose group
Rat body weight is less than model control group, there is significant difference, and high dose group is significantly lower than model group, has pole conspicuousness poor
It is different.To sum up point out, sample has the effect of certain mitigation obese model rat body weight.
Influence of the sample of table 2 to obese model rat food ration and body fat
Compare certainly with blank, #P ＜ 0.05, ##P ＜ 0.01；
Compare with model control group,*P ＜ 0.05**P ＜ 0.01.256.8±15.7##
As shown in Table 2, the food ration of each administration group rat is less than model control group, but compares that there was no significant difference；Examination
After testing end, model control group rat perirenal fat and genitals week fat are significantly lower than blank control group, have and extremely show
Sex differernce is write, hints model is successfully established；Administration group rat perirenal fat and genitals week fat are below model comparison
Group, wherein low dose group perirenal fat and high dose group perirenal fat and genitals week fat have significantly with model group contrast
Sex differernce.To sum up point out, sample successive administration 6 weeks, the food ration to obese model rat does not make significant difference, but can
To reduce the fat/body ratio of perirenal fat and genitals week fat.
Claims (10)
1. a kind of composition, it is characterised in that：By L-arabinose 1-4 weight portions, green coffee-extract 1-4 weight
Part and L- mulberry-leaf extract 1-4 weight portions composition.
2. composition according to claim 1, it is characterised in that：By L-arabinose 2-4 weight portions, green
Coffee-extract 1-2 weight portions and L- mulberry-leaf extract 1-2 weight portions are constituted.
3. composition according to claim 2, it is characterised in that：By the weight portion of L-arabinose 3, green coffee
The weight portion of coffee extract 2 and the weight portion of L- mulberry-leaf extracts 1 are constituted.
4. the composition according to any one of claim 1-3, it is characterised in that：The green coffee-extract
The mass percentage content of middle total chlorogenic acid is 10-70%, and the mass percentage content of DNJ is in mulberry-leaf extract
0.1-10%.
5. composition according to claim 4, it is characterised in that：Total chlorogenic acid in the green coffee-extract
Mass percentage content is 20-50%, and the mass percentage content of DNJ is 0.5-5% in mulberry-leaf extract.
6. composition according to claim 5, it is characterised in that：Total chlorogenic acid in the green coffee-extract
Mass percentage content is 20% or 50%, and the mass percentage content of DNJ is 1% or 5% in mulberry-leaf extract.
7. the composition according to any one of claim 1-6, it is characterised in that：The composition also contains
Edible auxiliary material and/or flavouring.
8. composition according to claim 7, it is characterised in that：The composition is oral formulations.
9. composition according to claim 5, it is characterised in that：The oral formulations are powder, pulvis, piece
Agent, granule or capsule.
10. the composition any one of claim 1-9, the food of blood sugar, reduction blood fat is reduced for preparing
The purposes of product, health food or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511020264.4A CN106912940A (en) | 2015-12-28 | 2015-12-28 | A kind of composition containing L-arabinose and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511020264.4A CN106912940A (en) | 2015-12-28 | 2015-12-28 | A kind of composition containing L-arabinose and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106912940A true CN106912940A (en) | 2017-07-04 |
Family
ID=59456300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511020264.4A Pending CN106912940A (en) | 2015-12-28 | 2015-12-28 | A kind of composition containing L-arabinose and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106912940A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109567201A (en) * | 2019-01-04 | 2019-04-05 | 无锡海尔偲生命科技有限公司 | For blocking composition and the application of human body parts fat and carbohydrate absorption |
| CN114190553A (en) * | 2020-09-17 | 2022-03-18 | 内蒙古蒙牛乳业（集团）股份有限公司 | Composition with weight-losing effect and application and preparation method thereof |
| CN118285510A (en) * | 2024-06-06 | 2024-07-05 | 成都衡美精研健康科技有限公司 | Composite probiotic composition for accelerating fat metabolism, preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953442A (en) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | Health care product with function of reducing blood sugar |
| CN105031041A (en) * | 2014-04-25 | 2015-11-11 | 康立为生医科技股份有限公司 | PLANT EXTRACT COMPOSITION, and pharmaceutical COMPOSITION and APPLICATION THEREOF |
-
2015
- 2015-12-28 CN CN201511020264.4A patent/CN106912940A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953442A (en) * | 2009-12-23 | 2011-01-26 | 济南圣泉唐和唐生物科技有限公司 | Health care product with function of reducing blood sugar |
| CN105031041A (en) * | 2014-04-25 | 2015-11-11 | 康立为生医科技股份有限公司 | PLANT EXTRACT COMPOSITION, and pharmaceutical COMPOSITION and APPLICATION THEREOF |
Non-Patent Citations (1)
| Title |
|---|
| 赵茜: "《全球热门报刊双语阅读精选 人文时尚》", 31 January 2013 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109567201A (en) * | 2019-01-04 | 2019-04-05 | 无锡海尔偲生命科技有限公司 | For blocking composition and the application of human body parts fat and carbohydrate absorption |
| CN114190553A (en) * | 2020-09-17 | 2022-03-18 | 内蒙古蒙牛乳业（集团）股份有限公司 | Composition with weight-losing effect and application and preparation method thereof |
| CN118285510A (en) * | 2024-06-06 | 2024-07-05 | 成都衡美精研健康科技有限公司 | Composite probiotic composition for accelerating fat metabolism, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103054113B (en) | Composite fruit-vegetable juice beverage with blood sugar decreasing effect | |
| CN106261439A (en) | Protein Diets fiber meal replacement powder and preparation method | |
| CN106912940A (en) | A kind of composition containing L-arabinose and application thereof | |
| CN106912920A (en) | A kind of composition containing mulberry-leaf extract and application thereof | |
| CN103750094B (en) | Male hachinoko health-care paste and preparation method thereof | |
| CN102526360B (en) | Health-care product with weight loss function | |
| CN104799286A (en) | Composition for improving immunity and preparation method of composition | |
| CN104667135A (en) | Pharmaceutical composition and health care product and preparation method | |
| CN101711840B (en) | Medicine-food dual-purpose composition suitable for cancerous patients and preparation method thereof | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN105920198B (en) | Cell wall-broken micropowder with blood replenishing effect and preparation method thereof | |
| CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
| CN111357891A (en) | Plant beverage containing artichoke and ginseng and preparation method thereof | |
| CN103005439B (en) | Bitter gourd compound lipid-lowering oral solution and preparation method thereof | |
| CN109122856A (en) | A kind of liver-protecting sober-up Chinese medicine composition | |
| CN110024941A (en) | A kind of composition and its application with blood-enrich function | |
| CN108450941A (en) | A kind of dietary composition adjusting lipid metaboli | |
| CN101336719B (en) | Nutrient powder capable of expelling toxin and preventing cancer | |
| CN105101817A (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN107468952A (en) | A kind of preparation method of the integration of drinking and medicinal herbs composition with auxiliary hyperglycemic function | |
| CN102343025B (en) | Aloe preparation and preparation method thereof | |
| CN106912945A (en) | A kind of composition containing green coffee-extract and application thereof | |
| CN105193993B (en) | A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes | |
| CN112057476B (en) | Composition and application thereof in sobering-up, hangover-relieving and stomach-protecting | |
| CN108967757A (en) | A kind of thickened red jujube ginger pulp production technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170704 |
|
| RJ01 | Rejection of invention patent application after publication |